Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
19 June 2024 - 6:05AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2024
Commission file number: 001-35223
BioLineRx Ltd.
(Translation of registrant’s name into English)
2 HaMa’ayan Street
Modi’in 7177871, Israel
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
On June 16, 2024, Biokine Therapeutics Ltd. (“Biokine”), filed
a complaint with the District Court of Jerusalem against BioLineRx Ltd. (the “Company”), entitled Biokine Therapeutics Ltd. v. BioLineRx Ltd., T.A. 31677-06-24. The complaint alleges breach of contract and a purported failure to make certain payments to Biokine under the Company’s in-licensing agreement with Biokine for motixafortide. The lawsuit seeks compensatory damages in the amount of approximately $6.5 million and a declaratory judgment in favor of Biokine. The Company intends to vigorously
defend itself against such action.
This report on Form 6-K is incorporated by reference into all effective registration statements filed by the registrant under the
Securities Act of 1933.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
|
|
BioLineRx Ltd.
|
|
|
|
|
|
|
By:
|
/s/ Philip A. Serlin
|
|
|
|
Philip A. Serlin
|
|
|
|
Chief Executive Officer
|
|
BioLineRx (NASDAQ:BLRX)
Historical Stock Chart
From Nov 2024 to Dec 2024
BioLineRx (NASDAQ:BLRX)
Historical Stock Chart
From Dec 2023 to Dec 2024
